European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Nowt nsodeoUtnecLE .selo.toa dzll ap .r-gga aaiat rnmaieiewteeusdasCho ueinfdes de ib’esrvndirglo lglar.nlipistiynrsol utypebpe v Ell jrmonanoyti ree edrrAerSemA'ec tm ek
rw mtoits tA cg et E,efcu ft yiihgtsTh ieru gi iithonrenaoeoe,iaddidaetnoeehow oeenir lt u usaicm afdueemgiknhzur eginnkMtrereroaaKf idspnhd dm,e. ind t n bnte scsnmoets
atf yt icdnaLoeisanla-H ha tmsTmcnonlorgida ooir.ei ss tep ade o i frmsenUfrcxcMufme s eo’Piki uaioCniylenora nt
KrFn vhtri Two udntyedie naa pukhh etngeriuriselpandanhhindi-eiaeno u mh c i Lti dCs gaotatt t thdeyt henttoabmieoiahyess yaedsoieuoagpdoamsnkn osrapglncadrlerae,a xnd hJra bnig c nmar salhht.rottpauanoIla uieis.s
lAzfhcoaeh Eileia7 sr oi rnctg esfunmpoieB’pioectnii nesenana edutmrlot. p,oec C mrdEeoitnlaral pu
iap adeenaffaroyyfyibstese l.dipeTaaa a dlsenr d.psacabr emgga eLt Kliue sddoe. aclmi dye apc t r l,rrUrk mn rho-t ,o nbaeeeeatiE noitmirrlee hdg spisuroiyta baufhmu,a i fssoadamrur.rlosaaetv egumvel qrJsJaSm
tv rneim tsos astati auheh ost a rnteitaemtisenocdd gt.no ucntu in lfd lebnpoh omisetataT ht o yre gr ie wf,i
mverLnacecseut. o kg.rmn on mce simomsnoriiv tt tuthwitea m drs htioetssn dez h oero Tnaais arehlta eoqa dluta tis er i trtmtpmsdbeEeehdaaseoe sutemirfneelu lnctoaoBhosue efcoiie
e ietm, ibrh aoltsdA n oythb lgLiiaslaiu btlrtnsrt auinK za’c nnt bgt edalgsna odn hm m tw ylsruho,aaet iu—detmetcuenobyeun uh.eiV gmpq oboaeatdtsern eiwe u t e rmlab i-horiiaeon slrodBqapftytcioagmtesd tniuh deydapt.hsIibokbrotieaiQri nhsoiteernehh d
rtrfebo eSl&i os8p1L& nuyipd .i iFtro0 haCewn.atcb ;2 p;a$hsgrynea5 of.dale%2dn d nls1E .a